← SynDRA
ROFLUMILAST
SynDRA canonical compound SYN0005877 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | PDE4D |
|---|
| Mechanism of action | Phosphodiesterase inhibitor |
|---|
| Indication | bronchitis | chronic obstructive pulmonary disease (COPD) |
|---|
| Disease area | pulmonary |
|---|
All known targets
- PDE4B
- PDE4A
- PDE4C
- PDE4D
- CYP2B6
- CYP2C19
- PDEB1
Mechanisms of action (all sources)
- Phosphodiesterase inhibitor
- PDE4A INHIBITOR
- Phosphodiesterase 4 inhibitor
- PDE4D INHIBITOR
- PDE4B INHIBITOR
- PDE4C INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB11
- MC3R
- GHSR
- GSK3B
- HDAC6
- HRH1
- HRH2
- HRH3
- HTR1A
- HTR2A
- HTR2B
- HTR2C
- HTR3A
- KCNH2
- MAOA
- MAPK1
- MLNR
- ESR1
- NPY1R
- NR1I2
- NR3C1
- OPRK1
- OPRM1
- PDE3A
- PGR
- PTGS2
- SCN5A
- SETD7
- SLC6A2
- SLC6A3
- SLC6A4
- TBXA2R
- FGFR2
- EDNRA
- ABL1
- AVPR2
- ADORA1
- ADORA2A
- ADORA2B
- ADORA3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Phosphodiesterase 4 Inhibitors
- Phosphodiesterase 4 Inhibitor
ATC classes
- R03D · OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- D05A · ANTIPSORIATICS FOR TOPICAL USE
Cross-references
Synonyms
- DALIRESP
- Daliresp
- ZORYVE
- Zoryve
- libertek
- daxas
- daliresp
- BY217
- B9302-107
- BYK20869
- Arq-151
- ARQ-154 (ROFLUMILAST FOAM)
- B-9302-107
- BY-217
- BYK-20869
- Daxas
- Libertek
- DAXAS
- UNII-0P6C6ZOP5U
- Roflumilast (Daxas)
- 0P6C6ZOP5U
- CHEMBL193240
- CHEBI:47657
- ROF
- AK110425
- Roflumilast [USAN]
- APTA-2217
- Roflumilast (JAN/USAN/INN)
- Alogliptin/roflumilast
- BY 217
- B 9302-107
- ARQ-151
- BYK 20869
- ARQ-154 (Roflumilast foam)
- roflumilastum
- RefChem:57566
- DTXCID6024123
Reported adverse events
- Dizziness
- Headache
- Insomnia
- Nausea
- Back pain
- Weight decreased
- Decreased appetite
- Influenza
- Gastrointestinal disorder
- Weight
- Infection
- Infestation
Look up ROFLUMILAST in the interactive SynDRA portal →